SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,300.00
-45.00 (-1.92%)
Mar 28, 2025, 3:30 PM KST
-51.75%
Market Cap 315.77B
Revenue (ttm) 3.93B
Net Income (ttm) -26.53B
Shares Out 137.29M
EPS (ttm) -220.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 472,029
Average Volume 525,485
Open 2,370.00
Previous Close 2,345.00
Day's Range 2,290.00 - 2,375.00
52-Week Range 2,270.00 - 5,230.00
Beta -0.16
RSI 34.81
Earnings Date Mar 24, 2025

About SillaJen

SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 37
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2024, SillaJen's revenue was 3.93 billion, a decrease of -0.33% compared to the previous year's 3.94 billion. Losses were -26.53 billion, 30.2% more than in 2023.

Financial Statements

News

There is no news available yet.